Anavex extends cash runway to three years as Alzheimer’s review continues

Anavex Life Sciences (NASDAQ:AVXL) reported a narrowed net loss and a robust cash position for its fiscal first quarter, providing the clinical-stage biotech with a three-year financial cushion as it contests a regulatory setback in Europe and prepares for pivotal U.S. filings.

The New York-based company reported a net loss of $5.7 million, or $0.06 per share, for the quarter ended Dec. 31, 2025—a significant improvement from the $12.1 million loss in the same period last year.

The narrowing loss was primarily driven by a sharp reduction in research and development expenses, which fell to $4.7 million as the company transitioned from active large-scale trials to the data-analysis and regulatory phases of its lead candidate, oral blarcamesine.

Anavex ended the quarter with $131.7 million in cash, which it estimates will fund operations into 2029.

The quarter was defined by intense regulatory activity for blarcamesine, the company’s "autophagy reactivator" designed to treat neurodegenerative diseases.

Following a negative opinion from the EU’s Committee for Medicinal Products for Human Use (CHMP) in late 2024, Anavex formally requested a re-examination of its marketing application for early Alzheimer’s disease.

Meanwhile, in the U.S., the company recently held a Type C meeting with the FDA, securing collaborative feedback on a potential New Drug Application (NDA) pathway for blarcamesine.

Beyond Alzheimer’s, Anavex is finalizing the design for a Phase 2/3 study in Fragile X syndrome and continues to progress its ANAVEX®3-71 program for schizophrenia.

With a lean burn rate and significant clinical data in hand for Parkinson’s and Rett syndrome, the company remains one of the most well-capitalized small-cap biotechs in the CNS space.